Skip to content

The study of ultrasound in screening and evaluating connective tissue disease associated interstitial lung disease and the construction of artificial intelligence evaluation model

The study of ultrasound in screening and evaluating connective tissue disease associated interstitial lung disease and the construction of artificial intelligence evaluation model

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400080909
Enrollment
Unknown
Registered
2024-02-18
Start date
2024-03-01
Completion date
Unknown
Last updated
2024-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

connective tissue disease associated interstitial lung disease

Interventions

Gold Standard:High Resolution Computed Tomography
Index test:Lung ultrasound examination

Sponsors

The First Affiliated Hospital, the Air Force Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. age 18~75 years old (including both ends); 2. Patients with systemic lupus erythematosus meet the 2012 EULAR/ACR classification criteria; 3. Patients with Sjogren's syndrome meet the 2016 EULAR/ACR classification criteria; 4. Patients with systemic scleroderma meet the 2013 EULAR/ACR classification criteria; 5. Patients with rheumatoid arthritis meet the 2010 EULAR/ACR classification standards; 6. Patients with polymyositis/dermatomyositis meet the 2017 EULAR/ACR classification criteria; 7. Other rare connective tissue diseases meet the respective EULAR/ACR classification standards; 8. the urine pregnancy test of women of childbearing age must be negative, and during the study, fertile women and men must voluntarily use recognized effective contraceptive measures; 9. informed consent, voluntary participation.

Exclusion criteria

Exclusion criteria: 1. Patients in the acute exacerbation period of interstitial lung disease must use large flow oxygen or ventilators; 2. Other lung lesions other than interstitial lung disease, such as: Patients with moderate to severe pulmonary hypertension requiring special treatment: patients with other serious lung disease clinical manifestations, such as lung masses or active lung infections; Lung tissue biopsy, alveolar lavage, or HRCT suggest other severe lung disease; 3. Patients with serious diseases of the heart, liver, kidney and other important organs, blood and endocrine system or serious malignant tumors, and the researchers believe that it may bring unacceptable risks to the patients participating in this study; 4. Patients with severe lung infection; 5. Interstitial lung diseases caused by drug toxicity, occupational, environmental, and radiation damage, such as pneumoconiosis, drugs such as bleomycin, immunosuppressants, etc.; 6. Pregnant and lactating women, or those of childbearing age who cannot guarantee effective contraception; 7. have serious mental illness (schizophrenia, depression, etc.); 8. Patients with incomplete medical records or unable to fully participate in the research process; 9. Other reasons why the researcher considers it inappropriate to participate in this experiment.

Design outcomes

Primary

MeasureTime frame
Lung ultrasound;ntraclass Correlation Coefficient,ICC;ROC curve;

Countries

China

Contacts

Public ContactDing Jin

The First Affiliated Hospital, the Air Force Medical University

dingjin@fmmu.edu.cn+86 135 7192 4635

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026